On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy | Zendy

YiJie Huang | Zendy; Chi-Sen Chang | Zendy; YenChun Peng | Zendy; HongZen Yeh | Zendy; ShengShun Yang | Zendy

Open Access

On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy

Author(s) -

YiJie Huang,

Chi-Sen Chang,

YenChun Peng,

HongZen Yeh,

ShengShun Yang

Publication year - 2017

Publication title -

journal of the chinese medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.535

H-Index - 42

eISSN - 1728-7731

pISSN - 1726-4901

DOI - 10.1016/j.jcma.2016.12.005

Subject(s) - medicine , entecavir , chronic hepatitis , hbeag , gastroenterology , virology , hepatitis b virus , lamivudine , virus , hbsag

Hepatitis B e antigen (HBeAg) status is associated with clinical outcomes, and seroconversion of HBeAg is one of the treatment goals. In this study, we determined the association of on-treatment serum hepatitis B virus (HBV) DNA levels in HBeAg-positive chronic hepatitis B patients who were receiving entecavir (ETV) treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research